Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | NCF1 | P14598 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | CCR8 | P51685 | 1/20 | 0.40 |
| ▸ | METAP1 | P53582 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.40 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quinoxaline SCHEMBL11665681 | 1.00 | ALDH1A1 (0.55) | ALDH1A1MAPTNCF1KDM4EPOLB | |
| Quinoxaline SCHEMBL27863276 | 0.97 | ALDH1A1 (0.52) | ALDH1A1MAPTNCF1KDM4EPOLB | |
| Quinoxaline SCHEMBL6928518 | 0.96 | ALDH1A1 (0.58) | ALDH1A1MAPTNCF1KDM4EPOLB | |
| Quinoxaline SCHEMBL5315 | 0.96 | ALDH1A1 (0.58) | ALDH1A1MAPTNCF1KDM4EPOLB | |
| Quinoxaline SCHEMBL30320908 | 0.96 | ALDH1A1 (0.58) | ALDH1A1MAPTNCF1KDM4EPOLB | |
| Quinoxaline SCHEMBL29355228 | 0.96 | ALDH1A1 (0.58) | ALDH1A1MAPTNCF1KDM4EPOLB | |
| Quinoxaline SCHEMBL2431603 | 0.93 | ALDH1A1 (0.55) | ALDH1A1MAPTNCF1KDM4EPOLB | |
| Quinoxaline SCHEMBL19877228 | 0.93 | ALDH1A1 (0.55) | ALDH1A1MAPTNCF1KDM4EPOLB | |
| Quinoxaline SCHEMBL20610240 | 0.93 | ALDH1A1 (0.55) | ALDH1A1MAPTNCF1KDM4EPOLB | |
| Quinoxaline SCHEMBL16053848 | 0.93 | ALDH1A1 (0.55) | ALDH1A1MAPTNCF1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112552313-B | Fused ring quinoxalinyl non-fullerene acceptor material and preparation method and application thereof | 华南理工大学 | 2022-03-29 | — | — | CN | claimed |
| CN-112552313-A | Fused ring quinoxalinyl non-fullerene acceptor material and preparation method and application thereof | 华南理工大学 | 2021-03-26 | — | — | CN | claimed |
| CN-1966500-A | Quinoxaline derivative, preparation method and uses | SHANGHAI INST MATERIA MEDICA (CN) | 2007-05-23 | — | — | CN | claimed |
| US-12115158-B2 | Survivin-targeting anti-tumor agents and uses thereof | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2024-10-15 | — | — | US | disclosed |
| CN-112552313-B | Fused ring quinoxalinyl non-fullerene acceptor material and preparation method and application thereof | 华南理工大学 | 2022-03-29 | — | — | CN | disclosed |
| US-20210299123-A1 | SURVIVIN-TARGETING ANTI-TUMOR AGENTS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-09-30 | — | — | US | disclosed |
| CN-112552313-A | Fused ring quinoxalinyl non-fullerene acceptor material and preparation method and application thereof | 华南理工大学 | 2021-03-26 | — | — | CN | disclosed |
| CN-108148064-B | Method for preparing pyrazole quinoxalinone derivative | 浙江百斯特化工有限公司 | 2020-06-26 | — | — | CN | disclosed |
| CN-108017640-A | A kind of novel quinoxaline class organic molecule and preparation method thereof | 南京科技职业学院 | 2018-05-11 | — | — | CN | disclosed |
| CN-107311945-A | Thiosemicarbazones part and preparation method thereof, thiosemicarbazones metal complex and preparation method thereof | 河南理工大学 | 2017-11-03 | — | — | CN | disclosed |
| CN-101878554-B | Oled device employing alkali metal cluster compounds | GLOBAL OLED TECHNOLOGY LLC | 2012-07-25 | — | — | CN | disclosed |
| CN-1966500-B | Quinoxaline derivative, preparation method and uses | SHANGHAI INST MATERIA MEDICA | 2011-03-30 | — | — | CN | disclosed |
| CN-101878554-A | Oled device employing alkali metal cluster compounds | EASTMAN KODAK CO | 2010-11-03 | — | — | CN | disclosed |
| US-7501416-B2 | Quinoxaline compounds and methods of using them | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-03-10 | — | — | US | disclosed |
| WO-2008015423-A1 | QUINOLINE AND QUINOXALINE N-OXIDES AS CHK-1 INHIBITORS | SENTINEL ONCOLOGY LIMITED (GB) | 2008-02-07 | — | — | WO | disclosed |
| CN-1966500-A | Quinoxaline derivative, preparation method and uses | SHANGHAI INST MATERIA MEDICA (CN) | 2007-05-23 | — | — | CN | disclosed |
| WO-2005077920-A1 | QUINOXALINE COMPOUNDS AND METHODS OF USING THEM | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-08-25 | — | — | WO | disclosed |
| US-20050176717-A1 | Quinoxaline compounds and methods of using them | BRISTOL-MYERS SQUIBB COMPANY | 2005-08-11 | — | — | US | disclosed |
| US-6548499-B1 | N-(1-Azabicyclo(2.2.2)octanyl-3-pyridinyl)-3-(2-pyridinyl)-2 -quinoxalinamine, for example; treating various chemokine mediated diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2003-04-15 | — | — | US | disclosed |
| WO-1999042463-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES AS INTERLEUKIN-8 RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1999-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176717-A1 | Quinoxaline compounds and methods of using them | NQO1, NQO2, SDHA | ALDH1A1 602/4885MAPT 3545/4885NCF1 1293/4885 |
| US-20210299123-A1 | SURVIVIN-TARGETING ANTI-TUMOR AGENTS AND USES THEREOF | XIAP, BIRC5, TP53 | ALDH1A1 2712/4885MAPT 3150/4885NCF1 1073/4885 |
| US-12115158-B2 | Survivin-targeting anti-tumor agents and uses thereof | XIAP, BIRC5, TP53 | ALDH1A1 2712/4885MAPT 3150/4885NCF1 1073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.